Related Experiment Video
Updated: Mar 26, 2026

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
Targeting hepatic TRAF1-ASK1 signaling to improve inflammation, insulin resistance, and hepatic steatosis
Mei Xiang1, Pi-Xiao Wang2, Ai-Bing Wang3
1Department of Cardiology, The Central Hospital of Wuhan, Wuhan, China; Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Animal Experiment Center/Animal Biosafety Level-III Laboratory, Wuhan University, Wuhan 430060, China.
Background & Aims:
Tumor necrosis factor receptor-associated factor 1 (TRAF1) is an important adapter protein that is largely implicated in molecular events regulating immunity/inflammation and cell death. Although inflammation is closely related to and forms a vicious circle with insulin dysfunction and hepatic lipid accumulation, the role of TRAF1 in hepatic steatosis and the related metabolic disorders remains unclear.
Methods:
The participation of TRAF1 in the initiation and progression of hepatic steatosis was evaluated in high fat diet (HFD)-induced and genetic obesity. Mice with global TRAF1 knockout or liver-specific TRAF1 overexpression were employed to investigate the role of TRAF1 in insulin resistance, inflammation, and hepatic steatosis based on various phenotypic examinations. Molecular mechanisms underlying TRAF1-regulated hepatic steatosis were further explored in vivo and in vitro.
Results:
TRAF1 expression was significantly upregulated in the livers of NAFLD patients and obese mice and in palmitate-treated hepatocytes. In response to HFD administration or in ob/ob mice, TRAF1 deficiency was hepatoprotective, whereas the overexpression of TRAF1 in hepatocytes contributed to the pathological development of insulin resistance, inflammatory response and hepatic steatosis. Mechanistically, hepatocyte TRAF1 promotes hepatic steatosis through enhancing the activation of ASK1-mediated P38/JNK cascades, as evidenced by the fact that ASK1 inhibition abolished the exacerbated effect of TRAF1 on insulin dysfunction, inflammation, and hepatic lipid accumulation.
Conclusions:
TRAF1 functions as a positive regulator of insulin resistance, inflammation, and hepatic steatosis dependent on the activation of ASK1-P38/JNK axis.
Insights
Tumor necrosis factor receptor-associated factor 1 (TRAF1) promotes liver fat accumulation and insulin resistance. Inhibiting TRAF1 may offer a therapeutic strategy for non-alcoholic fatty liver disease (NAFLD) and metabolic disorders.
Area of Science:
- Hepatology
- Molecular Biology
- Metabolic Disorders
Background:
- Tumor necrosis factor receptor-associated factor 1 (TRAF1) is an adapter protein involved in immunity and cell death.
- The role of TRAF1 in hepatic steatosis and related metabolic disorders, despite its link to inflammation and insulin dysfunction, remains unclear.
Purpose of the Study:
- To investigate the role of TRAF1 in the development of hepatic steatosis and associated metabolic disorders.
- To elucidate the molecular mechanisms by which TRAF1 influences insulin resistance, inflammation, and lipid accumulation in the liver.
Main Methods:
- Evaluation of TRAF1's role in high-fat diet-induced and genetic obesity models.
- Utilizing global TRAF1 knockout and liver-specific TRAF1 overexpression mice for phenotypic examinations.
- In vivo and in vitro studies to explore molecular mechanisms.
Main Results:
- TRAF1 expression is upregulated in NAFLD patients, obese mice, and palmitate-treated hepatocytes.
- TRAF1 deficiency showed hepatoprotective effects, while its overexpression exacerbated insulin resistance, inflammation, and hepatic steatosis.
- TRAF1 promotes hepatic steatosis by activating the ASK1-mediated P38/JNK pathway.
Conclusions:
- TRAF1 acts as a positive regulator in insulin resistance, inflammation, and hepatic steatosis.
- This regulation is dependent on the activation of the ASK1-P38/JNK axis.
- Targeting TRAF1 may be a potential therapeutic approach for metabolic liver diseases.
More Related Videos
Related Concept Videos
Insulin: The Receptor and Signaling Pathways
Pharmacogenomics: Identification of New Drug Targets
PI3K/mTOR/AKT Signaling Pathway

